Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of HGT-HIT-094 for intrathecal idursulfase in Hunter syndrome with cognitive impairment
2014-004143-13Phase 2Unknown
- Sponsor
- Takeda
- Start
- Jan 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idursulfase in mucopolysaccharidosis type 2, sponsored by Takeda. Primary endpoint: Long-term safety. Status: unknown.
02
Drugs
idursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2014-004143-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004143-13.